Results 41 to 50 of about 852 (150)

Assessment of the global and national market for lipid modifying agents: retrospective and innovation

Сибирский научный медицинский журнал, 2023
Lipid-lowering therapy is one of the most important aspects in the treatment of patients with cardiovascular disease, which is still the leading cause of death in the adult population.
A. V. Lokhmacheva, S. G. Fominykh, L. V. Trubina, I. E. Sikhvardt   +3 more
doaj   +1 more source

The High Price of Interrupted Follow‐Up: Catastrophic Progression of Homozygous Familial Hypercholesterolemia—A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder, primarily resulting from mutations in LDLR, APOB, and PCSK9 genes. These mutations cause persistently high levels of low‐density lipoprotein cholesterol (LDL‐C), predisposing affected individuals to premature atherosclerotic cardiovascular disease (ASCVD ...
Parham Dastjerdi, Mahdieh Aghababaei, Reza Nikfar, Maryam Aghakouchakzadeh, Reza Mohseni‐Badalabadi, Kaveh Hosseini   +5 more
wiley   +1 more source

Adipokine in Metabolic Liver Disease: Adipo–Brain–Liver Cross talk

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Purpose Adipokines play a key role in the interaction between the brain, liver, and adipose tissue. In this review, we selected adipokines with wide central receptor expression and summarized their indirect regulation on liver metabolism by acting on specific neurons and inducing neuropeptide production.
Yule Su, Yiping Yang, Wenjuan Sun, Zhouxi Yu, Yilin Wang, Shixin Liu, Ziyi Chen, Yanfei Li, Xi Yang, Junyan Liu, Caikun Han, Yaqin Wang, Junhua Yuan, Suraiya Saleem   +13 more
wiley   +1 more source

Homozygous familial hypercholesterolemia, experience with Evinacumab treatment in two Mexican pediatric patients: case report

Frontiers in Genetics
Homozygous familial hypercholesterolemia (HoFH) is a rare and life-threatening genetic disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels from birth, leading to accelerated atherosclerotic cardiovascular ...
Ramón Madriz Prado, Yazmín Guadalupe Ríos Solís, Diana Estefanía Guerrero Dávila, Lucía Molina Fernández, Omar Spencer Aguilar Reyes, Ilse Ordóñez, Leticia Ramos, Marisol González   +7 more
doaj   +1 more source

Statins Regulate Stem Cell Growth Factor‐β to Balance Osteogenesis and Adipogenesis in Mesenchymal Stem Cells, Endowing Anti‐Osteonecrosis Effects

Journal of Cellular and Molecular Medicine, Volume 29, Issue 22, November 2025.
ABSTRACT Dyslipidaemia has been implicated in osteonecrosis through some clinical studies. However, a direct causal relationship between hyperlipidaemia and osteonecrosis remains unconfirmed, and whether lipid‐lowering agents could be used to treat osteonecrosis remains unclear.
Fangzhou Fan, Yu Chen, Weiyan Peng, Wenlong Yan, Hao Tan, Chengxuan Zhang, Siyu Tan, Qian Xiao, Yuan Gao, Jian Zhang, Lei Liu, Chengjie Lian   +11 more
wiley   +1 more source

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids

Diabetes, Obesity and Metabolism, Volume 27, Issue 10, Page 5985-5995, October 2025.
Abstract Aims The aim of this study was to determine if retatrutide, a triple agonist of glucose‐dependent insulinotropic polypeptide (GIP) receptor, glucagon‐like peptide 1 (GLP‐1) receptor and glucagon (GCG) receptor, may lower serum triglyceride (TG) and low‐density lipoprotein cholesterol (LDL‐C) levels in part by decreasing circulating ...
Yi Wen, Deven Lemen, Yanzhu Lin, Yan Q. Chen, Ajit Regmi, William C. Roell, Melissa K. Thomas, Mark L. Hartman, Tamer Coskun, Zvonko Milicevic, Axel Haupt, Giacomo Ruotolo, Robert J. Konrad   +12 more
wiley   +1 more source

Achieving the impossible: effective reduction of low-density lipoprotein cholesterol (LDL-C) in a patient with homozygous familial hypercholesterolemia

Endokrynologia Polska
Not required for Clinical Vignette.
Mateusz Maligłówka, Aleksandra Sojka, Adrianna Dec, Bogusław Okopień, Łukasz Bułdak   +4 more
doaj   +1 more source

Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. [PDF]

Eur Heart J
Abstract Background and Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by severely elevated LDL cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease.
Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, Stefanutti C, Stroes E, Wiegman A, Turner T, Ali S, Banerjee P, Drewery T, McGinniss J, Waldron A, George RT, Zhao XQ, Pordy R, Zhao J, Bruckert E, Raal FJ.   +20 more
europepmc   +5 more sources

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, Volume 27, Issue S8, Page 34-46, September 2025.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Beyond lipids: Systemic effects of lipoprotein apheresis

Transfusion, Volume 66, Issue 3, Page 590-598, March 2026.
Menatalla Nadim, Yamac Akgun
wiley   +1 more source